Objective: The objective of this study was to demonstrate the feasibility of timely multimodal
MRI screening before thrombolysis in acute stroke patients. Methods: Quality improvement …

Objective: The purpose of this study was to demonstrate that the median door-to-needle
(DTN) time for intravenous tissue plasminogen activator (tPA) treatment can be reduced to …

BACKGROUND AND PURPOSE: Although MRI may provide much information on brain
pathology to aid in patient selection for thrombolysis, the concern remains that MRI …

Background and Purpose—MRI screening for thrombolytic therapy may improve patient
selection. Alternatively, it may excessively delay treatment and thereby lead to worse …

Objective To investigate differences in procedure times, safety, and efficacy outcomes
comparing 2 different protocols to enable thrombolysis in the extended or unknown time …

Objectives–The study analyzes feasibility and time‐delays in Magnetic resonance imaging
(MRI) based thrombolysis and estimate the impact of MRI on individual tissue plasminogen …

Intravenous tissue plasminogen activator (tPA) remains the only level 1A treatment for acute
ischemic stroke. The results of several prospective randomized trials comparing tPA with …

Since the approval of intravenous (IV) tissue plasminogen activator (tPA) to treat patients
with acute ischaemic stroke (AIS) within 3 hours of onset in 1996, it took 12 years to expand …

acute ischemic stroke treatment. The most important event was the publication of the meta-
analysis of the recent large stroke trials, including NINDS, ECASS, and ATLANTIS. 20 This …

ABSTRACT INTRODUCTION Favorable outcomes in intraarterial therapy (IAT) for acute
ischemic stroke (AIS) are related to early vessel recanalization. The mobile stroke treatment …